Craig-Hallum lowered the firm’s price target on Avadel Pharmaceuticals (AVDL) to $17 from $23 and keeps a Buy rating on the shares. Despite the disappointing guidance for 2025, the company expects strong demand to continue, with 2,800-3,000 patients expected to initiate therapy in 2025, the analyst tells investors in a research note. The firm thinks guidance may prove conservative as it assumes persistency rates continue to worsen and the company is not able to drive improvement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Piper Sandler cuts Avadel Pharmaceuticals price target, says staying bullish
- Avadel Pharmaceuticals price target lowered to $21 from $25 at H.C. Wainwright
- Avadel Pharmaceuticals price target lowered to $19 from $22 at Needham
- Closing Bell Movers: Penguin Solutions up 16% on earnings beat
- Avadel Pharmaceuticals Projects Robust Growth for LUMRYZ